Idera Pharmaceuticals Inc was incorporated in Delaware on May 25, 1989. The Company is a clinical stage biotechnology company. The Company is engaged in the discovery, development and commercialization of novel therapeutics for oncology and rare diseases. The Company uses two distinct proprietary drug discovery technology platforms to design and develop drug candidates including nucleic acid therapeutics that target biologic pathways implicated in disease processes. The Company first platform focuses on inhibiting over-activation of Toll-like receptors (TLRs) and the second is its gene silencing oligonucleotides (GSOs) platform. The Company TLR antagonist drug candidates are IMO-8400 and IMO-9200, which are both antagonists of TLR7, TLR8 and TLR9. The Company also has created compounds that are agonists of TLR3, TLR7, TLR8 and TLR9. Its TLR agonist drug candidates are IMO-2055 and IMO-2125, which are both agonists of TLR9. The Company's drug candidates include IMO-8400 an novel synthetic oligonucleotide antagonist of TLR7, TLR8, and TLR9. It is developing IMO-8400 for the treatment of certain genetically defined forms of B-cell lymphoma and for the treatment of rare diseases. It is also conducting a Phase 1 clinical trial of IMO-9200 in healthy subjects, as well as additional preclinical studies of IMO-9200 for a selected autoimmune disease. The Company relies upon third parties to produce material for nonclinical and clinical testing purposes. The Company's competitors include Dynavax, InDex Pharmaceuticals AB, Mologen AG, BioLineRx Ltd., Innate Immunotherapeutics Ltd., VentiRx Pharmaceuticals Inc., Telormedix S.A., Gilead Sciences Inc., GlaxoSmithKline plc, AstraZeneca plc and Hoffmann-La Roch. The testing, manufacturing, labeling, advertising, promotion, export, and marketing of its drug candidates are subject to regulation by governmental authorities in Europe, the United States, and elsewhere throughout the world.
Benzinga is a fast-growing, dynamic and innovative financial media outlet that empowers investors with high-quality, unique content.